Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
Chemical Synapses01:26

Chemical Synapses

8.6K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.6K
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

40
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
40
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

601
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
601
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

855
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
855
Cross-bridge Cycle01:26

Cross-bridge Cycle

116.6K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
116.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reversible Acute Chorea in a Patient on Hemodialysis.

Annals of Indian Academy of Neurology·2026
Same author

Variables associated with clinical outcomes and switching from unilateral to bitemporal electroconvulsive therapy: a retrospective study.

Frontiers in psychiatry·2026
Same author

Editorial: Surgical approaches and outcomes in cervical and thoracic myelopathies.

Frontiers in surgery·2026
Same author

The effects of EXOPULSE Mollii Suit in patients with fibromyalgia: a double-blind randomized sham-controlled trial (EXOFIB2).

Pain medicine (Malden, Mass.)·2026
Same author

Evolving electroconvulsive therapy practices at a French psychiatric hospital: A retrospective study.

L'Encephale·2025
Same author

Optimizing subthalamic deep brain stimulation for treatment-refractory obsessive compulsive disorder: A practical guide to advanced parameter tuning.

Brain stimulation·2025

Related Experiment Video

Updated: May 26, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.4K

Alexithymia in multiple sclerosis: past, present and future.

Samar S Ayache1,2,3,4, Moussa A Chalah1,2,5

  • 1Department of Neurology, Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon.

Frontiers in Human Neuroscience
|February 24, 2025
PubMed
Summary
This summary is machine-generated.

Alexithymia, difficulty identifying emotions, affects up to 53% of multiple sclerosis (MS) patients. Understanding its correlates and neurobiology is crucial for managing MS and improving patient outcomes.

Keywords:
alexithymiaanxietydepressionfatigueinteroceptionmultiple sclerosisneurobiologypsychotherapy

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.7K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

8.6K

Related Experiment Videos

Last Updated: May 26, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.4K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.7K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

8.6K

Area of Science:

  • Neuroscience
  • Psychology
  • Clinical Medicine

Background:

  • Alexithymia, characterized by difficulty identifying and expressing emotions, is a personality trait affecting ~10% of the general population.
  • It is a risk factor for various health problems, psychopathologies, and poor treatment outcomes, often observed in neurological diseases.
  • In multiple sclerosis (MS), alexithymia prevalence reaches up to 53%, yet remains understudied.

Purpose of the Study:

  • To review the prevalence, clinical, sociodemographic, and neuropsychological correlates of alexithymia in MS.
  • To analyze the neurobiological underpinnings of alexithymia in MS using neurophysiological and neuroimaging data.
  • To offer perspectives for future research on alexithymia assessment and management in MS.

Main Methods:

  • Literature review of alexithymia in multiple sclerosis.
  • Analysis of clinical, sociodemographic, and neuropsychological data.
  • Examination of neurophysiological and neuroimaging studies.

Main Results:

  • Alexithymia is highly prevalent in MS patients (up to 53%).
  • Correlates include anxiety, depression, fatigue, and socio-emotional outcomes.
  • Neurobiological underpinnings are being explored through neuroimaging and neurophysiological studies.

Conclusions:

  • Alexithymia is a significant, understudied issue in multiple sclerosis.
  • Further research into its mechanisms, assessment, and management is needed.
  • Understanding alexithymia in MS can improve patient care and treatment outcomes.